EP0932680A2 - Compositions et procedes destines a la prevention et au diagnostic de l'ehrlichiose granulocytaire humaine - Google Patents
Compositions et procedes destines a la prevention et au diagnostic de l'ehrlichiose granulocytaire humaineInfo
- Publication number
- EP0932680A2 EP0932680A2 EP97909914A EP97909914A EP0932680A2 EP 0932680 A2 EP0932680 A2 EP 0932680A2 EP 97909914 A EP97909914 A EP 97909914A EP 97909914 A EP97909914 A EP 97909914A EP 0932680 A2 EP0932680 A2 EP 0932680A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- aohge
- polypeptide
- polypeptides
- kda
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 113
- 206010071038 Human anaplasmosis Diseases 0.000 title abstract description 60
- 201000009163 human granulocytic anaplasmosis Diseases 0.000 title abstract description 60
- 208000022340 human granulocytic ehrlichiosis Diseases 0.000 title abstract description 60
- 239000000203 mixture Substances 0.000 title abstract description 48
- 230000002265 prevention Effects 0.000 title abstract description 12
- 238000003745 diagnosis Methods 0.000 title abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 560
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 551
- 229920001184 polypeptide Polymers 0.000 claims abstract description 546
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 121
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 90
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 82
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 72
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 72
- 239000012634 fragment Substances 0.000 claims abstract description 67
- 230000001681 protective effect Effects 0.000 claims abstract description 52
- 229960005486 vaccine Drugs 0.000 claims abstract description 46
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims description 133
- 210000004027 cell Anatomy 0.000 claims description 75
- 108020004414 DNA Proteins 0.000 claims description 62
- 241001465754 Metazoa Species 0.000 claims description 48
- 230000003053 immunization Effects 0.000 claims description 44
- 238000002649 immunization Methods 0.000 claims description 43
- 239000002253 acid Substances 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 230000002163 immunogen Effects 0.000 claims description 19
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 238000004458 analytical method Methods 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 238000001262 western blot Methods 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims 16
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 13
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 154
- 235000018102 proteins Nutrition 0.000 description 82
- 210000001744 T-lymphocyte Anatomy 0.000 description 63
- 230000014509 gene expression Effects 0.000 description 43
- 210000003719 b-lymphocyte Anatomy 0.000 description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 42
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 34
- 201000010099 disease Diseases 0.000 description 34
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 241000238876 Acari Species 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 25
- 239000013598 vector Substances 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 23
- 230000004224 protection Effects 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 241000605314 Ehrlichia Species 0.000 description 20
- 230000028993 immune response Effects 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 238000001514 detection method Methods 0.000 description 16
- 238000011081 inoculation Methods 0.000 description 16
- 239000002671 adjuvant Substances 0.000 description 15
- 230000000875 corresponding effect Effects 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 238000003119 immunoblot Methods 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 208000016604 Lyme disease Diseases 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 239000003155 DNA primer Substances 0.000 description 10
- 102000005720 Glutathione transferase Human genes 0.000 description 10
- 108010070675 Glutathione transferase Proteins 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 101800001509 Large capsid protein Proteins 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 208000000292 ehrlichiosis Diseases 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 241000605281 Anaplasma phagocytophilum Species 0.000 description 9
- 201000008680 babesiosis Diseases 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 241000589969 Borreliella burgdorferi Species 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000003714 granulocyte Anatomy 0.000 description 7
- 201000002364 leukopenia Diseases 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 6
- QNJNPKSWAHPYGI-JYJNAYRXSA-N Glu-Phe-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 QNJNPKSWAHPYGI-JYJNAYRXSA-N 0.000 description 6
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 208000035056 Tick-Borne disease Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 5
- 238000000729 Fisher's exact test Methods 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 5
- 239000002751 oligonucleotide probe Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 4
- 238000011735 C3H mouse Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- LLBQJYDYOLIQAI-JYJNAYRXSA-N Leu-Glu-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LLBQJYDYOLIQAI-JYJNAYRXSA-N 0.000 description 4
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108700006640 OspA Proteins 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 4
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- ONWMQORSVZYVNH-UWVGGRQHSA-N Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ONWMQORSVZYVNH-UWVGGRQHSA-N 0.000 description 4
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 108010038633 aspartylglutamate Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 201000009162 human monocytic ehrlichiosis Diseases 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 108010034529 leucyl-lysine Proteins 0.000 description 4
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000032163 Emerging Communicable disease Diseases 0.000 description 3
- UVTSZKIATYSKIR-RYUDHWBXSA-N Gly-Tyr-Glu Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O UVTSZKIATYSKIR-RYUDHWBXSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010020429 Human ehrlichiosis Diseases 0.000 description 3
- 241000238703 Ixodes scapularis Species 0.000 description 3
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 238000002944 PCR assay Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 241000589970 Spirochaetales Species 0.000 description 3
- AAZOYLQUEQRUMZ-GSSVUCPTSA-N Thr-Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O AAZOYLQUEQRUMZ-GSSVUCPTSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005802 health problem Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 2
- QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 description 2
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 2
- CJQAEJMHBAOQHA-DLOVCJGASA-N Ala-Phe-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CJQAEJMHBAOQHA-DLOVCJGASA-N 0.000 description 2
- 241000606646 Anaplasma Species 0.000 description 2
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 2
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 2
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 2
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 2
- KZXPVYVSHUJCEO-ULQDDVLXSA-N Arg-Phe-Lys Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 KZXPVYVSHUJCEO-ULQDDVLXSA-N 0.000 description 2
- YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 description 2
- OGZBJJLRKQZRHL-KJEVXHAQSA-N Arg-Thr-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OGZBJJLRKQZRHL-KJEVXHAQSA-N 0.000 description 2
- QUBKBPZGMZWOKQ-SZMVWBNQSA-N Arg-Trp-Arg Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 QUBKBPZGMZWOKQ-SZMVWBNQSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 2
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 2
- ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 description 2
- YNSCBOUZTAGIGO-ZLUOBGJFSA-N Asn-Asn-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)N YNSCBOUZTAGIGO-ZLUOBGJFSA-N 0.000 description 2
- QISZHYWZHJRDAO-CIUDSAMLSA-N Asn-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N QISZHYWZHJRDAO-CIUDSAMLSA-N 0.000 description 2
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 2
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 2
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 2
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 2
- QJMCHPGWFZZRID-BQBZGAKWSA-N Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O QJMCHPGWFZZRID-BQBZGAKWSA-N 0.000 description 2
- RZNAMKZJPBQWDJ-SRVKXCTJSA-N Asn-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N RZNAMKZJPBQWDJ-SRVKXCTJSA-N 0.000 description 2
- HMUKKNAMNSXDBB-CIUDSAMLSA-N Asn-Met-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMUKKNAMNSXDBB-CIUDSAMLSA-N 0.000 description 2
- OMSMPWHEGLNQOD-UWVGGRQHSA-N Asn-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UWVGGRQHSA-N 0.000 description 2
- HZZIFFOVHLWGCS-KKUMJFAQSA-N Asn-Phe-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O HZZIFFOVHLWGCS-KKUMJFAQSA-N 0.000 description 2
- AWXDRZJQCVHCIT-DCAQKATOSA-N Asn-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O AWXDRZJQCVHCIT-DCAQKATOSA-N 0.000 description 2
- SZNGQSBRHFMZLT-IHRRRGAJSA-N Asn-Pro-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SZNGQSBRHFMZLT-IHRRRGAJSA-N 0.000 description 2
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 description 2
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 2
- WUQXMTITJLFXAU-JIOCBJNQSA-N Asn-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N)O WUQXMTITJLFXAU-JIOCBJNQSA-N 0.000 description 2
- AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 description 2
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 2
- DATSKXOXPUAOLK-KKUMJFAQSA-N Asn-Tyr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DATSKXOXPUAOLK-KKUMJFAQSA-N 0.000 description 2
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 2
- DPWDPEVGACCWTC-SRVKXCTJSA-N Asn-Tyr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O DPWDPEVGACCWTC-SRVKXCTJSA-N 0.000 description 2
- XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 2
- MYRLSKYSMXNLLA-LAEOZQHASA-N Asn-Val-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MYRLSKYSMXNLLA-LAEOZQHASA-N 0.000 description 2
- PAYPSKIBMDHZPI-CIUDSAMLSA-N Asp-Leu-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PAYPSKIBMDHZPI-CIUDSAMLSA-N 0.000 description 2
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 2
- HRVQDZOWMLFAOD-BIIVOSGPSA-N Asp-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)O HRVQDZOWMLFAOD-BIIVOSGPSA-N 0.000 description 2
- NWAHPBGBDIFUFD-KKUMJFAQSA-N Asp-Tyr-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O NWAHPBGBDIFUFD-KKUMJFAQSA-N 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 241000223836 Babesia Species 0.000 description 2
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SBMGKDLRJLYZCU-BIIVOSGPSA-N Cys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N)C(=O)O SBMGKDLRJLYZCU-BIIVOSGPSA-N 0.000 description 2
- ANPADMNVVOOYKW-DCAQKATOSA-N Cys-His-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ANPADMNVVOOYKW-DCAQKATOSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 2
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 2
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 2
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 2
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 description 2
- MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 description 2
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 2
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 2
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 2
- JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 2
- VAXIVIPMCTYSHI-YUMQZZPRSA-N Gly-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN VAXIVIPMCTYSHI-YUMQZZPRSA-N 0.000 description 2
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 2
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 2
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 2
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 2
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- YOSQCYUFZGPIPC-PBCZWWQYSA-N His-Asp-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YOSQCYUFZGPIPC-PBCZWWQYSA-N 0.000 description 2
- VFBZWZXKCVBTJR-SRVKXCTJSA-N His-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VFBZWZXKCVBTJR-SRVKXCTJSA-N 0.000 description 2
- WRPDZHJNLYNFFT-GEVIPFJHSA-N His-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O WRPDZHJNLYNFFT-GEVIPFJHSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000238681 Ixodes Species 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QLROSWPKSBORFJ-BQBZGAKWSA-N L-Prolyl-L-glutamic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 QLROSWPKSBORFJ-BQBZGAKWSA-N 0.000 description 2
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 2
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 2
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 2
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 2
- MDVZJYGNAGLPGJ-KKUMJFAQSA-N Leu-Asn-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MDVZJYGNAGLPGJ-KKUMJFAQSA-N 0.000 description 2
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 2
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 2
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 2
- IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 2
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 2
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 2
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 2
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 2
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 2
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 2
- SEOXPEFQEOYURL-PMVMPFDFSA-N Leu-Tyr-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SEOXPEFQEOYURL-PMVMPFDFSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 2
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 2
- DGWXCIORNLWGGG-CIUDSAMLSA-N Lys-Asn-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O DGWXCIORNLWGGG-CIUDSAMLSA-N 0.000 description 2
- GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 description 2
- WGLAORUKDGRINI-WDCWCFNPSA-N Lys-Glu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGLAORUKDGRINI-WDCWCFNPSA-N 0.000 description 2
- PINHPJWGVBKQII-SRVKXCTJSA-N Lys-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N PINHPJWGVBKQII-SRVKXCTJSA-N 0.000 description 2
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 2
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 2
- ZJSZPXISKMDJKQ-JYJNAYRXSA-N Lys-Phe-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=CC=C1 ZJSZPXISKMDJKQ-JYJNAYRXSA-N 0.000 description 2
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 2
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 2
- KXYLFJIQDIMURW-IHPCNDPISA-N Lys-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CCCCN)=CNC2=C1 KXYLFJIQDIMURW-IHPCNDPISA-N 0.000 description 2
- AWMMBHDKERMOID-YTQUADARSA-N Lys-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCCN)N)C(=O)O AWMMBHDKERMOID-YTQUADARSA-N 0.000 description 2
- XYLSGAWRCZECIQ-JYJNAYRXSA-N Lys-Tyr-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=C(O)C=C1 XYLSGAWRCZECIQ-JYJNAYRXSA-N 0.000 description 2
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- GRKPXCKLOOUDFG-UFYCRDLUSA-N Met-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 GRKPXCKLOOUDFG-UFYCRDLUSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000699691 Peromyscus leucopus Species 0.000 description 2
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 2
- WMGVYPPIMZPWPN-SRVKXCTJSA-N Phe-Asp-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N WMGVYPPIMZPWPN-SRVKXCTJSA-N 0.000 description 2
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 description 2
- XNQMZHLAYFWSGJ-HTUGSXCWSA-N Phe-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XNQMZHLAYFWSGJ-HTUGSXCWSA-N 0.000 description 2
- DBNGDEAQXGFGRA-ACRUOGEOSA-N Phe-Tyr-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DBNGDEAQXGFGRA-ACRUOGEOSA-N 0.000 description 2
- MHNBYYFXWDUGBW-RPTUDFQQSA-N Phe-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O MHNBYYFXWDUGBW-RPTUDFQQSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 2
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 2
- SXMSEHDMNIUTSP-DCAQKATOSA-N Pro-Lys-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SXMSEHDMNIUTSP-DCAQKATOSA-N 0.000 description 2
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 2
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 2
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- OWCVUSJMEBGMOK-YUMQZZPRSA-N Ser-Lys-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O OWCVUSJMEBGMOK-YUMQZZPRSA-N 0.000 description 2
- CRJZZXMAADSBBQ-SRVKXCTJSA-N Ser-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO CRJZZXMAADSBBQ-SRVKXCTJSA-N 0.000 description 2
- PBUXMVYWOSKHMF-WDSKDSINSA-N Ser-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CO PBUXMVYWOSKHMF-WDSKDSINSA-N 0.000 description 2
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 2
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 2
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 2
- PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ZUXQFMVPAYGPFJ-JXUBOQSCSA-N Thr-Ala-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN ZUXQFMVPAYGPFJ-JXUBOQSCSA-N 0.000 description 2
- YLXAMFZYJTZXFH-OLHMAJIHSA-N Thr-Asn-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YLXAMFZYJTZXFH-OLHMAJIHSA-N 0.000 description 2
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 2
- VUSAEKOXGNEYNE-PBCZWWQYSA-N Thr-His-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VUSAEKOXGNEYNE-PBCZWWQYSA-N 0.000 description 2
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 2
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 2
- JLNMFGCJODTXDH-WEDXCCLWSA-N Thr-Lys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O JLNMFGCJODTXDH-WEDXCCLWSA-N 0.000 description 2
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 2
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 2
- 208000004374 Tick Bites Diseases 0.000 description 2
- IKUMWSDCGQVGHC-UMPQAUOISA-N Trp-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)O IKUMWSDCGQVGHC-UMPQAUOISA-N 0.000 description 2
- DANHCMVVXDXOHN-SRVKXCTJSA-N Tyr-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DANHCMVVXDXOHN-SRVKXCTJSA-N 0.000 description 2
- PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 2
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 2
- CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 2
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 2
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 2
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 2
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- -1 amino, carboxyl Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 2
- 108010094001 arginyl-tryptophyl-arginine Proteins 0.000 description 2
- 108010068380 arginylarginine Proteins 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 108010068265 aspartyltyrosine Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 108010059898 glycyl-tyrosyl-lysine Proteins 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 108010012581 phenylalanylglutamate Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 2
- 108010071207 serylmethionine Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PIDRBUDUWHBYSR-UHFFFAOYSA-N 1-[2-[[2-[(2-amino-4-methylpentanoyl)amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O PIDRBUDUWHBYSR-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical group OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 1
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 1
- BSGSDLYGGHGMND-IHRRRGAJSA-N Arg-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N BSGSDLYGGHGMND-IHRRRGAJSA-N 0.000 description 1
- SLQQPJBDBVPVQV-JYJNAYRXSA-N Arg-Phe-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O SLQQPJBDBVPVQV-JYJNAYRXSA-N 0.000 description 1
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- UCHSVZYJKJLPHF-BZSNNMDCSA-N Asp-Phe-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UCHSVZYJKJLPHF-BZSNNMDCSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000020089 Atacta Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241001200922 Gagata Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- WUYLWZRHRLLEGB-AVGNSLFASA-N Met-Met-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O WUYLWZRHRLLEGB-AVGNSLFASA-N 0.000 description 1
- QQPMHUCGDRJFQK-RHYQMDGZSA-N Met-Thr-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QQPMHUCGDRJFQK-RHYQMDGZSA-N 0.000 description 1
- 241001314546 Microtis <orchid> Species 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 241000604969 Neorickettsia sennetsu Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241000144952 Peromyscus californicus Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 241000607124 Salmonella enterica subsp. enterica serovar Muenchen Species 0.000 description 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 1
- ZXLUWXWISXIFIX-ACZMJKKPSA-N Ser-Asn-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZXLUWXWISXIFIX-ACZMJKKPSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- RQXDSYQXBCRXBT-GUBZILKMSA-N Ser-Met-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RQXDSYQXBCRXBT-GUBZILKMSA-N 0.000 description 1
- LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 208000006730 anaplasmosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- XKNKHVGWJDPIRJ-UHFFFAOYSA-N arsanilic acid Chemical compound NC1=CC=C([As](O)(O)=O)C=C1 XKNKHVGWJDPIRJ-UHFFFAOYSA-N 0.000 description 1
- 229950002705 arsanilic acid Drugs 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 108010031071 cholera toxoid Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 239000011507 gypsum plaster Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- XZNXVSDNACTASG-RZNNTOFGSA-M sodium;3,5-diacetamido-2,4,6-triiodobenzoate;3,5-diacetamido-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XZNXVSDNACTASG-RZNNTOFGSA-M 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000001064 tick infestation Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to compositions and methods useful for studying the pathogenicity of and for the prevention, treatment and diagnosis of human granulocytic ehrlichiosis (HGE) .
- HGE human granulocytic ehrlichiosis
- this invention relates to polypeptides and DNA sequences which encode them, from the agent of HGE, referred to herein as "aoHGE".
- aoHGE agent of HGE
- Such polypeptides and DNA sequences are useful to detect the presence of aoHGE in humans, to diagnose human granulocytic ehrlichiosis and related disorders caused by aoHGE infection, and to elicit an immune response which is effective to prevent or lessen the severity, for some period of time, of aoHGE infection.
- This invention also relates to vaccines comprising aoHGE, one or more of the aoHGE polypeptides or antibodies of this invention. Also within the scope of this invention are diagnostic kits comprising the aoHGE polypeptides, DNA sequences encoding them or antibodies of this invention.
- This invention also relates to methods for selecting protective aoHGE polypeptides and antibodies. Methods for using the aforementioned polypeptides, DNA sequences and antibodies are also within the scope of this invention.
- the causative agent of human granulocytic ehrlichiosis is a recently identified bacteria of the genus Ehrlichia which has not yet been named. It is sometimes referred to as E. microti or as "the agent of HGE" [S.R. Telford et al., "Perpetuation of the Agent of Human Granulocytic Ehrlichiosis In a Deer Tick- Rodent Cycle," Proc . Na tl . Acad. Sci . USA, 93, pp. 6209-6214 (1996)].
- the Ehrlichia which causes human granulocytic ehrlichiosis will be referred to herein as "aoHGE.”
- the tick vector has been shown to be Ixodes scapulari s (also referred to as Ixodes dammini ) in the Ixodes ri cinus complex [S. et al . , Proc . Na tl . Acad. Sci . USA, 93, supra ] .
- Ticks acquire aoHGE by feeding on an infected host. Humans are infected by the bite of infected ticks. Not unexpectedly, the disease is prevalent in regions of the country where Lyme disease and babesiosis, diseases also associated with I. scapularis, are common [L.A.
- human granulocytic ehrlichiosis is becoming a recognized human health problem in endemic areas and the incidence of the disease is expected to rise over the next several years.
- Human granulocytic ehrlichiosis is transmitted by ticks that carry a number of different pathogens including Babesia mi croti , the agent of babesiosis, and Borrelia burgdorferi , the agent of Lyme disease.
- a greater understanding of human granulocytic ehrlichiosis may provide insight into clinical symptoms that result in misdiagnosis of other tick-borne infections, most notably Lyme disease.
- the present invention solves the problems referred to above by providing means to study, diagnose, prevent and treat aoHGE infection and human granulocytic ehrlichiosis and related disorders caused by aoHGE infection. More particularly, this invention provides aoHGE polypeptides, DNA sequences that encode the polypeptides, antibodies directed against the polypeptides and compositions and methods comprising the aoHGE polypeptides, DNA sequences and antibodies. This invention further provides a single or multicomponent vaccine comprising aoHGE or one or more aoHGE polypeptides or antibodies of this invention.
- This invention provides DNA sequences that code for the aoHGE polypeptides of this invention, recombinant DNA molecules that are characterized by those DNA sequences, unicellular hosts transformed with those DNA seq ent s and molecules, and methods of using those sequences, molecules and hosts to produce the aoHGE polypeptides and multicomponent vaccines of this invention.
- DNA sequences of this invention are also advantageously used in methods and means for the diagnosis of aoHGE infection and human granulocytic ehrlichiosis .
- diagnostic means and methods characterized by aoHGE polypeptides, DNA sequences encoding them or antibodies directed against these polypeptides. These means and methods are useful for the detection of human granulocytic ehrlichiosis and aoHGE infection. They are also useful in following the course of treatment against such infection. In patients previously inoculated with the vaccines of this invention, the detection means and methods disclosed herein are also useful for determining if booster inoculations are appropriate.
- This invention further provides an immunocompetent, non-human, mammalian model for human granulocytic ehrlichiosis for use in studying the pathology of the disease and in screening for aoHGE polypeptides and antibodies that are capable of protecting a treated subject against aoHGE infection or human granulocytic ehrlichiosis and related disorders caused by aoHGE infection.
- this invention also provides methods for the identification and isolation of additional aoHGE polypeptides, as well as compositions and methods comprising such polypeptides.
- Figure 1A-D depicts the DNA and amino acid sequences of the E6 polypeptide of aoHGE isolate NCH-1 (SEQ ID NOS: 1 and 2) .
- Figure 2A-D depicts the DNA and amino acid sequences of the E7 polypeptide of aoHGE isolate NCH-1 (SEQ ID NOS: 3 and 4) .
- Figure 3 depicts the amino acid sequence of the 44-1 polypeptide from the 44 kDa protein of aoHGE isolate NCH-1 (SEQ ID NO: 5) .
- Figure 4 depicts the amino acid sequence of the 44-2 polypeptide from the 44 kDa protein of aoHGE isolate NCH-1 (SEQ ID NO: 6) .
- Figure 5A-B depicts the DNA sequence of the 44 kDa protein of aoHGE isolate NCH-1 (SEQ ID NO: 10) .
- Figure 6 depicts the amino acid sequence of the 44 kDa protein of aoHGE isolate NCH-1 (SEQ ID NO: ) , and indicates the position of the 44-1 and 44-2 polypeptides.
- Figure 7 depicts the amino acid sequence of the 80-1 polypeptide from the 80 kDa protein of aoHGE isolate NCH-1 (SEQ ID NO: 7) .
- x indicates the amino acid positions in which a characteristic chromatogram was not obtained.
- Figure 8 shows the ELISA and IFA antibody titers in sera from aoHGE infected mice to aoHGE-HL-60 antigen at 10, 17 and 24 days after tick-borne infection. Titers are expressed as the last positive 2-fold reciprocal dilution of serum, 4 mice/interval.
- Figure 9 shows immunoblot results of serum samples from 18 aoHGE patients. Titers 1:80 and above were considered positive. ND: not done, a: acute serum, c: convalescent serum. For patient 18, there were two convalescent sera, one at 3 weeks and one at 6 weeks after tick bite.
- Figure 10 depicts the 5' and 3' primers used to amplify the e ⁇ gene (SEQ ID NOS: 8 and 9) .
- the underlined portion of the 3' primer indicates the inserted Xhol site.
- the underlined portion of the 5' primer indicates the inserted EcoRI site.
- Figure 11A-C depicts the DNA sequence of the eM4 polypeptide of aoHGE isolate NCH-1 (SEQ ID NO: 12) .
- Figure 12A-B depicts the amino acid sequence of the eM4 polypeptide of aoHGE isolate NCH-1 (SEQ ID NO: 12).
- Figure 13A-B depicts the DNA sequence designated E5-3A (SEQ ID NO: ), which was isolated from a genomic aoHGE isolate NCH-1 library using oligonucleotide probes derived from the 44-kDa DNA sequence (SEQ ID NO: 10) .
- Figure 14A-B depicts the DNA sequence designated E5-3B (SEQ ID NO: ), which was isolated from a genomic aoHGE isolate NCH-1 library using oligonucleotide probes derived from the 44-kDa DNA sequence (SEQ ID NO: 10) .
- Figure 15A-B depicts the DNA sequence designated E5-5A (SEQ ID NO: ), which was isolated from a genomic aoHGE isolate NCH-1 library using oligonucleotide probes derived from the 44-kDa DNA sequence (SEQ ID NO: 10) .
- Figure 16 depicts the DNA sequence designated E5-5B (SEQ ID NO: ) , which was isolated from a genomic aoHGE isolate NCH-1 library using oligonucleotide probes derived from the 44-kDa DNA sequence (SEQ ID NO: 10) .
- Figure 17A-C depicts the DNA sequence designated E5-6 (SEQ ID NO: ) , which was isolated from a genomic aoHGE isolate NCH-1 library using oligonucleotide probes derived from the 44-kDa DNA sequence (SEQ ID NO: 10) .
- Figure 18 is a matrix plot depicting a region of homology between approximately nucleotides 200-400 and 600-1000 the E5-3B DNA sequence and approximately nucleotides 400-600 and 900-1200, respectively, of the 44-kDa DNA sequence.
- Figure 19 is a matrix plot depicting a region of homology between approximately nucleotides 300-650 of the E5-5B DNA sequence and approximately nucleotides 900-1200 of the 44-kDa DNA sequence.
- Figure 20 is a matrix plot depicting a region of homology between approximately nucleotides 1000-1400 and 1700-1900 of the E5-5B DNA sequence and approximately nucleotides 400-600 and 900-1300 of the 44-kDa DNA sequence.
- This invention relates to aoHGE polypeptides and DNA sequences encoding them, antibodies directed against those polypeptides, compositions comprising the polypeptides, DNA sequences or antibodies, and methods for identifying additional aoHGE polypeptides and antibodies and methods for the detection, treatment and prevention of human granulocytic ehrlichiosis and related disorders ⁇ aused by aoHGE infection.
- this invention provides a 40-kDa aoHGE polypeptide and compositions and methods comprising the polypeptide.
- this invention provides a 44-kDa aoHGE polypeptide and fragments 44-1 and 44-2 thereof, ind compositions and methods comprising the polypeptide and fragments.
- this invention provides a 65-kDa aoHGE polypeptide and compositions and methods comprising the polypeptide. In another embodiment, this invention provides a 80-kDa aoHGE polypeptide and the 80-1 fragment thereof, and compositions and methods comprising the polypeptide and fragment. In another embodiment, this invention provides a 94-kDa aoHGE polypeptide and compositions and methods comprising the polypeptide.
- this invention provides a 105-kDa aoHGE polypeptide and compositions and methods comprising the polypeptide.
- this invention provides a 110-kDa aoHGE polypeptide and compositions and methods comprising the polypeptide.
- this invention provides a 115-kDa aoHGE polypeptide and compositions and methods comprising the polypeptide.
- this invention provides a 125-kDa aoHGE polypeptide and compositions and methods comprising the polypeptide. In another embodiment, this invention provides an E6 polypeptide and compositions and methods comprising the polypeptide.
- this invention provides an E7 polypeptide encoded and compositions and methods comprising the polypeptide.
- this invention provides an eM4 polypeptide encoded and compositions and methods comprising the polypeptide.
- this invention provides an E5-3A, E5-3B, E5-5A, E5-5B and E5-6 DNA ssequences, and compositions and methods comprising them.
- the preferred compositions and methods of each of the aforementioned embodiments are characterized by immunogenic aoHGE polypeptides.
- an "immunogenic aoHGE polypeptide" is any aoHGE polypeptide that, when administered to an animal, is capable of eliciting a corresponding antibody.
- immunogenic aoHGE polypeptides are intended to include additional aoHGE polypeptides which may be identified according to the methods disclosed herein.
- compositions and methods of each of the aforementioned embodiments are characterized by aoHGE polypeptides which elicit in treated animals, the formation of an immune response which is effective to prevent or lessen the severity, for some period of time, of aoHGE infection.
- this invention provides a vaccine comprising aoHGE, one or more aoHGE polypeptides of this invention or one or more antibodies directed against aoHGE or a polypeptide of this invention.
- aoHGE polypeptides provided by this invention are substantially free of an Ehrli chia bacterium or fragments thereof, and thus may be used in a variety of applications without the risk of unintentional infection or contamination with undesired Ehrlichia components. Accordingly, the aoHGE polypeptides of this invention are particularly advantageous in compositions and methods for the diagnosis and prevention of aoHGE infection.
- a polypeptide that is "substantially free of an Ehrli chia bacterium or fragments thereof" is a polypeptide that, when introduced into an animal susceptible to aoHGE infection, fails to produce any Ehrlichia bacteria detectable by microscopic examination of a blood or tissue smear, by PCR amplification using aoHGE specific primers, by m si tu hybridization with aoHGE specific probes or by any other method for detecting aoHGE infection.
- it is a polypeptide that is detectable as a single band on an immunoblot probed with polyclonal anti-aoHGE anti-serum.
- this invention provides immunodominant aoHGE polypeptides.
- an "immunodominant aoHGE polypeptide” denotes an aoHGE polypeptide, or derivative thereof, that is recognized by antibodies elicited by infection with aoHGE, but which is substantially less reactive with antibodies elicited by infection with other bacteria.
- an "immunodominant region" of an aoHGE polypeptide denotes a region of an aoHGE polypeptide, or derivatives thereof, that is recognized by antibodies elicited by aoHGE infection but that is substantially less reactive than the full-length aoHGE protein when reacted with antibodies elicited by infection with other bacteria.
- substantially less reactive means, that when reacted in an ELISA or on an immunoblot with patient serum which contains antibodies elicited by infection with bacteria other than aoHGE, the level of reactivity would be at least 10-fold lower than the level of reactivity with serum from patients infected with aoHGE .
- the immunodominant polypeptides would be bound at a level at least 50-fold lower than the level of binding that occurs with antibodies in sera from patients infected with aoHGE. Most preferably, there would be no detectable binding.
- this invention provides antibodies directed against the aoHGE polypeptides of this invention, and pharmaceutically effective compositions and methods comprising those antibodies.
- the antibodies of this embodiment are those that are reactive with the aoHGE polypeptides of this invention, and are effective to diagnose, treat or protect against aoHGE infection and human granulocytic ehrlichiosis.
- Such antibodies may be used in a variety of applications, including to detect the presence of aoHGE, to screen for expression of novel aoHGE polypeptides, to purify novel aoHGE polypeptides, to block or bind to the aoHGE polypeptides, to direct molecules to the surface of aoHGE or aoHGE infected cells and to prevent or lessen the severity, for some period of time, of aoHGE infection.
- this invention relates to diagnostic means and methods characterized by the aoHGE polypeptides, DNA sequences or antibodies of the invention.
- This invention further provides an immunocompetent nonhuman, mammalian model for human HGE.
- the laborato__, mouse model, described herein, is characterized by clinical features that closely mimic HGE in humans.
- the mouse model is useful for selecting the preferred aoHGE polypeptides and antibodies of this invention that are effective to protect against aoHGE infection and human granulocytic ehrlichiosis .
- a further embodiment of this invention is a novel diagnostic assay for detecting the presence of aoHGE in a biological sample.
- the assay provided herein tests the ability of the biological sample to produce aoHGE infection in infant laboratory mice.
- the infant mice are 5 days old or less.
- the mice are 3 days old or less.
- the mice are 1 day of age.
- an "aoHGE polypeptide” is a polypeptide encoded by a DNA sequence of aoHGE.
- aoHGE polypeptides include the 40, 44, 65, 80, 94, 110, 115, or 125-kDa polypeptide expressed by aoHGE, as described in Example I, infra, an E6, E7 or eM4 polypeptide or fragments or derivatives thereof.
- an "aoHGE polypeptide” includes polypeptides encoded by a DNA sequence of any organism that causes HGE.
- a "40-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of Ehrlichia bacterium or fragments thereof and which is selected from the group consisting of:
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with a 40-kDa aoHGE polypeptide of (a) or (b) or (c) ;
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and the 40-kDa aoHGE polypeptide of (a) or
- aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with a 40-kDa aoHGE polypeptide of (a) or (b) or (c) .
- a "44-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with a polypeptide of (a) -(f);
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and a polypeptide of (a) -(f);
- a "65-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- a derivative of a 65-kDa aoHGE polypeptide of (a) or (b) said derivative being at least 80% identical in amino acid sequence to the corresponding polypeptide of (a) or (b) ;
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with a 65-kDa aoHGE polypeptide of (a) or (b) or (c) ;
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and the 65-kDa aoHGE polypeptide of (a) or
- aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with a 65-kDa aoHGE polypeptide of (a) or (b) or (c) .
- an "80-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- a "94-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of Ehrli chi a bacterium or fragments thereof and which is selected from the group consisting of:
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with a 94-kDa aoHGE polypeptide of (a) or (b) or (c) ;
- aoHGE polypeptides than are capable of eliciting antibodies that are immunologically reactive with aoHGE and a 94-kDa aoHGE polypeptide of (a) or (b) or (c) ; and (f) aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with a 94-kDa aoHGE polypeptide of (a) or (b) or (c) .
- a "105-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive witn a 105-kDa aoHGE polypeptide of (a) or (b) or (c) ;
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and a 105-kDa aoHGE polypeptide of (a) or
- aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with a 105-kDa aoHGE polypeptide of (a) or (b) or (c) .
- a "110-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with a 110-kDa aoHGE polypeptide of (a) or (b) or (c) ;
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and a 110-kDa aoHGE polypeptide of (a) or
- aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with a 110-kDa aoHGE polypeptide of (a) or (b) or (c) .
- a "115-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of
- Ehrli chia bacterium or fragments thereof which is selected from the group consisting of: (a) a 115-kDa aoHGE protein appearing as a single band on a Western blot after reacting with sera from an animal infected with aoHGE, and serotypic variants thereof;
- a derivative of a 115-kDa aoHGE polypeptide of (a) or (b) said derivative being at least 80% identical in ammo acid sequence to the corresponding polypeptide of (a) or (b) ;
- aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with a 115-kDa aoHGE polypeptide of (a) or (b) or (c) .
- a "125-kDa aoHGE polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with a 125-kDa aoHGE polypeptide of (a) or (b) or (c) ;
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and a 125-kDa aoHGE polypeptide of (a) or
- aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with a 125-kDa aoHGE polypeptide of (a) or (b) or (c) .
- an "E6 polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- a derivative of an E6 polypeptide of (a) or (b) said derivative being at least 80% identical in amino acid sequence to the corresponding polypeptide of (a) or (b);
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with an E6 polypeptide of (a) or (b) or (c) ;
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and an E6 polypeptide of (a) or (b) or (c) ;
- an "E7 polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- aoHGE polypeptide ⁇ that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with an E7 polypeptide of (a) - (c);
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and an E7 polypeptide of (a) -(c); and (g) aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with an E7 polypeptide of (a) -(c).
- an "eM4 polypeptide” denotes a polypeptide which is substantially free of Ehrli chia bacterium or fragments thereof and which is selected from the group consisting of:
- aoHGE polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with aoHGE, which antibodies are immunologically reactive with a polypeptide of (a) or (b) or (c);
- aoHGE polypeptides that are capable of eliciting antibodies that are immunologically reactive with aoHGE and a polypeptide of (a) or (b) or (c) ; and (f) aoHGE polypeptides that are immunologically reactive with antibodies elicited by immunization with a polypeptide of (a) or (b) or (c) .
- a "serotypic variant" of an aoHGE polypeptide of this invention also referred to herein as a “variant” is any naturally occurring aoHGE polypeptide which may be encoded, in whole or in part, by a DNA sequence which hybridizes, at 20-27°C below Tm, to any portion of the DNA sequence encoding the aoHGE polypeptide disclosed herein.
- aoHGE polypeptides include those polypeptides encoded by DNA sequences of which any portion may be amplified by using the polymerase chain reaction and oligonucleotide primers derived from any portion of the DNA sequence encoding the aoHGE polypeptide.
- a "protective aoHGE polypeptide” is any aoHGE polypeptide that, when administered to an animal, is capable of eliciting an immune response that is effective to prevent or lessen the severity, for some period of time, of aoHGE infection or HGE.
- Preventing or lessening the severity of infection may be evidenced by a change in the physiological manifestations of aoHGE infection, including fever, myalgia, arthralgia, anemia, leukocytopenia, thrombocytopenia, neutropenia, elevated hepatic enzyme levels, gastro-intestinal or pulmonary hemorrhaging and other disorders caused by aoHGE infection.
- aoHGE infection including fever, myalgia, arthralgia, anemia, leukocytopenia, thrombocytopenia, neutropenia, elevated hepatic enzyme levels, gastro-intestinal or pulmonary hemorrhaging and other disorders caused by aoHGE infection.
- it may be evidenced by a decrease in the level of aoHGE in infected ticks which have fed on treated animals.
- probes and oligonucleotide primers derived from the DNA encoding an aoHGE ⁇ polypeptide may be used to isolate and clone further variants of aoHGE proteins from other aoHGE isolates and perhaps from other rickettsia as well, which are useful in the methods and compositions of this invention.
- a "derivative" an aoHGE polypeptide is a polypeptide in which one or more physical, chemical, or biological properties has been altered.
- Such modifications include, but are not limited to: amino acid substitutions, modifications, additions or deletions; alterations in the pattern of lipidation, glycosylation or phosphorylation; reactions of free amino, carboxyl, or hydroxyl side groups of the amino acid residues present in the polypeptide with other organic and non-organic molecules; and other modifications, any of which may result in changes in primary, secondary or tertiary structure.
- a "protective epitope” is (1) an epitope which is recognized by a protective antibody, and/or (2) an epitope which, when used to immunize an animal, elicits an immune response sufficient to prevent or lessen the severity for some period of time, of aoHGE infection or HGE.
- preventing or lessening the severity of infection may be evidenced by a change in the physiological manifestations of aoHGE infection including fever, myalgia, arthralgia, anemia, leukocytopenia, thrombocytopenia, neutropenia, elevated hepatic enzyme levels, gastro-intestinal or pulmonary hemorrhaging, and other related disorders.
- a protective epitope may comprise a T cell epitope, a B cell epitope, or combinations thereof.
- a "protective antibody” is an antibody that confers protection, for some period of time, against aoHGE infection or any one of the physiological disorders associated with aoHGE infection or HGE.
- T cell epitope is an epitope which, when presented to T cells by antigen presenting cells, results in a T cell response such as clonal expansion or expression of lymphokines or other irrvrtiunostimulatory molecules.
- a T cell epitope may also be an epitope recognized by cytotoxic T cells that may affect intracellular aoHGE infection.
- a strong T cell epitope is a T cell epitope which elicits a strong T cell response.
- B cell epitope is the simplest spatial conformation of an antigen which reacts with a specific antibody.
- a "therapeutically effective amount" of a polypeptide or of an antibody is the amount that, when administered to an animal, elicits an. immune response that is effective to prevent or lessen the severity, for some period of time, of aoHGE infection.
- an “an anti-aoHGE polypeptide antibody, " also referred to as “an antibody of this invention, " is an antibody directed against an aoHGE polypeptide of this invention.
- an antibody of this invention may be directed against a 40-kDa, 44-kDa, 65-kDa, 80-kDa, 94-KDa, 110-kDa, 115- kDa, 125-kDa polypeptide expressed by aoHGE, as described in Example I, infra, an E6, E7 or eM4 polypeptide, or a fragment, derivative or serotypic variant of the aforementioned polypeptides.
- An anti- aoHGE polypeptide antibody of this invention includes antibodies directed against polypeptides expressed by aoHGE, or fragments or derivatives thereof, that are immunologically cross-reactive with any one of the aforementioned polypeptides.
- an anti-aoHGE polypeptide antibody of this invention includes antibodies directed against other aoHGE polypeptides identified according to methods taught herein.
- an "anti-aoHGE polypeptide antibody” is an immunoglobulin molecule, or portion thereof, that is immunologically reactive with an aoHGE polypeptide of the present invention and that was either elicited by immunization with aoHGE or an aoHGE polypeptide of this invention or was isolated or identified by its reactivity with an aoHGE polypeptide of this invention.
- An anti-aoHGE polypeptide antibody may be an intact immunoglobulin molecule or a portion of an immunoglobulin molecule that contains an intact antigen binding site, including those portions known in the art as F(v), Fab, Fab' and F(ab')2. It should be understood that an anti-aoHGE polypeptide antibody may also be a protective antibody.
- the aoHGE polypeptides disclosed herein are immunologically reactive with antisera generated by infection of a mammalian host with aoHGE . Accordingly, they are useful in methods and compositions to diagnose human granulocytic ehrlichiosis, and in therapautic compositions to stimulate immunological clearance of aoHGE during ongoing infection. In addition, because at least some, if not all of the aoHGE polypeptides disclosed herein are protective surface proteins of aoHGE, they are particularly useful in single and multicomponent vaccines against human granulocytic ehrlichiosis.
- multicomponent vaccines are preferred because such vaccines may be formulated to more closely resemble the immunogens presented by replication- competent aoHGE, and because such vaccines are more likely to confer broad-spectrum protection than a vaccine comprising only a single aoHGE polypeptide.
- Multicomponent vaccines according to this invention may also contain polypeptides which characterize other vaccines useful for immunization against diseases other than human granulocytic ehrlichiosis such as, for example, Lyme disease, human monocytic ehrlichiosis, babesiosis, diphtheria, polio, hepatitis, and measles. Such multicomponent vaccines are typically incorporated into a single composition.
- compositions and methods of this invention comprise aoHGE polypeptides having enhanced immunogenicity.
- Such polypeptides may result when the native forms of the polypeptides or fragments thereof are modified or subjected to treatments to enhance their immunogenic character in the intended recipient.
- aoHGE polypeptides of this invention may be modified by coupling to dinitrophenol groups or arsanilic acid, or by denaturation with heat and/or SDS.
- the polypeptides are small, chemically synthesized polypeptides, it may be desirable to couple them to an immunogenic carrier.
- the coupling must not interfere with the ability of either the polypeptide or the carrier to function appropriately.
- Useful immunogenic carriers are well known in the art.
- examples of such carriers are keyhole limpet hemocyanm (KLH) ; albumins such as bovme serum albumin (BSA) and ovalbumm, PPD (purified protein derivative of tuberculin) ; red blood cells; tetanus toxoid; cholera toxoid; agarose beads; activated carbon; or bentonite.
- KLH keyhole limpet hemocyanm
- BSA bovme serum albumin
- PPD purified protein derivative of tuberculin
- red blood cells tetanus toxoid
- cholera toxoid agarose beads
- activated carbon or bentonite.
- Modification of the ammo acid sequence of the aoHGE polypeptides disclosed herein in order to alter the lipidation state is also a method which may be used to increase their lmmunogenicity or alter their biochemical properties.
- the polypeptides may also be prepared with the objective of increasing stability or rendering the molecules more amenable to purification and preparation.
- One such technique is to express the polypeptides as fusion proteins comprising other aoHGE or non-aoHGE sequences.
- derivatives of the aoHGE polypeptides may be prepared by a variety of methods, including by m vi tro manipulation of the DNA encoding the native polypeptides and subsequent expression of the modified DNA, by chemical synthesis of derivatized DNA sequences, or by chemical or biological manipulation of expressed amino acid sequences.
- derivatives may be produced by substitution of one or more amino acids with a different natural amino acid, an amino acid derivative or non-native amino acid.
- conservative substitution is preferred, e.g., 3-methylhistidine may be substituted for histidine, 4-hydroxyproline may be substituted for proline, 5-hydroxylysine may be substituted for lysine, and the like.
- Causing amino acid substitutions which are less conservative may also result in desired derivatives, e.g., by causing changes in charge, conformation and other biological properties.
- substitutions would include for example, substitution of a hydrophilic residue for a hydrophobic residue, substitution of a cysteine or proline for another residue, substitution of a residue having a small side chain for a residue having a bulky side chain or substitution of a residue having a net positive charge for a residue having a net negative charge.
- the derivatives may be readily assayed according to the methods disclosed herein to determine the presence or absence of the desired characteristics.
- the immunogenicity, immunodominance and/or protectiveness of a derivative of this invention can be readily determined using methods disclosed in the Examples.
- the aoHGE polypeptides disclosed herein are prepared as part of a larger fusion protein.
- an aoHGE polypeptide of this invention may be fused at its N- terminus or C-terminus to a different immunogenic aoHGE polypeptide, to a non-aoHGE polypeptide or to combinations thereof, to produce fusion proteins comprising the aoHGE polypeptide.
- fusion proteins comprising aoHGE polypeptides are constructed comprising B cell and/or T cell epitopes from multiple serotypic variants of aoHGE, each variant differing from another with respect to the locations or sequences of the epitopes within the polypeptide.
- fusion proteins are constructed which comprise one or more of the aoHGE polypeptides fused to other aoHGE polypeptides. Such fusion proteins are particularly effective in the prevention, treatment and diagnosis of human granulocytic ehrlichiosis as caused by a wide spectrum of aoHGE isolates.
- the aoHGE polypeptides are fused to moieties, such as immunoglobulin domains, which may increase the stability and prolong the in vivo plasma half-life of the polypeptide.
- moieties such as immunoglobulin domains
- Such fusions may be prepared without undue experimentation according to methods well known to those of skill in the art, for example, in accordance with the teachings of United States patent 4,946,778, or United States patent 5,116,964.
- the exact site of the fusion is not critical as long as the polypeptide retains the desired biological activity. Such determinations may be made according to the teachings herein or by other methods known to those of skill in the art.
- the fusion proteins comprising the aoHGE polypeptides be produced at the DNA level, e.g., by constructing a nucleic acid molecule encoding the fusion protein, transforming host cells with the molecule, inducing the cells to express the fusion protein, and recovering the fusion protein from the cell culture.
- the fusion proteins may be produced after gene expression according to known methods.
- the aoHGE polypeptides may also be part of larger multimeric molecules which may be produced recombinantly or may be synthesized chemically. Such multimers may also include the polypeptides fused or coupled to moieties other than amino acids, including lipids and carbohydrates.
- the multimeric proteins will consist of multipxe T or B cell epitopes or combinations thereof repeated within the same molecule, either randomly, or with spacers (amino acid or otherwise) between them.
- aoHGE is incorporated into a vaccine. As disclosed in
- Examples and , animals immunized with such a vaccine produce antibodies that confer protection against aoHGE infection.
- an aoHGE polypeptide of this invention which is also a protective aoHGE polypeptide is incorporated into a single component vaccine.
- aoHGE polypeptides of this invention which are also protective aoHGE polypeptides are incorporated into a multicomponent vaccine comprising other protective aoHGE polypeptides.
- a multicomponent vaccine may also contain protective polypeptides useful for immunization against other diseases such as, for example, Lyme disease, human monocytic ehrlichiosis, babesiosis, diphtheria, polio, hepatitis, and measles.
- Such a vaccine by virtue of its ability to elicit antibodies to a variety of protective aoHGE polypeptides, will be effective to protect against human granulocytic ehrlichiosis as caused by a broad spectrum of different aoHGE isolates, even those that may not express one or more of the aoHGE proteins.
- the multicomponent vaccine may contain the aoHGE polypeptides as part of a multimeric molecule m which the various components are covalently associated. Alternatively, it may contain multiple individual components.
- a multicomponent vaccine may be prepared comprising two or more of the aoHGE polypeptides, wherein each polypeptide is expressed and purified from independent cell cultures and the polypeptides are combined prior to or during formulation.
- a multicomponent vaccine may be prepared from heterodimers or tetramers wherein the polypeptides have been fused to immunoglobulin chains or portions thereof.
- a vaccine could comprise, for example, a 44-kDa aoHGE polypeptide fused to an immunoglobulin heavy chain and an E6 aoHGE polypeptide fused to an immunoglobulin light chain, and could be produced by transforming a host cell with DNA encoding the heavy chain fusion and DNA encoding the light chain fusion.
- the host cell selected should be capable of assembling the two chains appropriately.
- the heavy and light chain fusions could be produced from separate cell lines and allowed to associate after purification.
- the multicomponent vaccine will comprise numerous T cell and B cell epitopes of protective aoHGE polypeptides.
- aoHGE polypeptides of this invention may be administered to an animal via a liposome delivery system in order to enhance their stability and/or immunogenicity .
- Delivery of the aoHGE polypeptides via liposomes may be particularly advantageous because the liposome may be internalized by phagocytic cells in the treated animal. Such cells, upon ingesting the liposome, would digest the liposomal membrane and subsequently present the polypeptides to the immune system in conjunction with other molecules required to elicit a strong immune response.
- the liposome system may be any variety of unilamellar vesicles, multilamellar vesicles, or stable plurilamellar vesicles, and may be prepared and administered according to methods well known to those of skill in the art, for example in accordance with the teachings of United States patents 5,169,637, 4,762,915, 5,000,958 or 5,185,154.
- any of the aoHGE polypeptides of this invention may be used in the form of a pharmaceutically acceptable salt.
- Suitable acids and bases which are capable of forming salts with the polypeptides of the present invention are well known to those of skill in the art, and include inorganic and organic acids and bases .
- this invention we describe a method which comprises the steps of treating an animal with a therapeutically effective amount of an aoHGE polypeptide, or a fusion protein or a multimeric protein comprising an aoHGE polypeptide, in a manner sufficient to prevent or lessen the severity, for some period of time, of aoHGE infection.
- the polypeptides that are preferred for use in such methods are those that contain protective epitopes.
- Such protective epitopes may be B cell epitopes, T cell epitopes, or combinations thereof.
- a method which comprises the steps of treating an animal with a multicomponent vaccine comprising a therapeutically effective amount of an aoHGE polypeptide, or a fusion protein or multimeric protein comprising such polypeptide in a manner sufficient to prevent or lessen the severity, for some period of time, of aoHGE infection.
- the polypeptides, fusion proteins and multimeric proteins that are preferred for use in such methods are those that contain protective epitopes, which may be B cell epitopes, T cell epitopes, or combinations thereof.
- polypeptides, fusion proteins and multimeric proteins for use in these compositions and methods are those containing both strong T cell and B cell epitopes. Without being bound by theory, we believe that this is the best way to stimulate high titer antibodies that are effective to neutralize aoHGE infection.
- Such preferred polypeptides will be internalized by B cells expressing surface immunoglobulin that recognizes the B cell epitope (s). The B cells will then process the antigen and present it to T cells. The T cells will recognize the T cell epitope (s) and respond by proliferating and producing lymphokines which in turn cause B cells to differentiate into antibody producing plasma cells.
- a closed autocatalytic circuit exists which will result in the amplification of both B and T cell responses, leading ultimately to production of a strong immune response which includes high titer antibodies against the aoHGE polypeptide.
- T H 1 T-helper cells type 1
- T H 2 T-helper cells type 2
- T H 1 or T H 2 cells may also be favored by the mode of administration of the polypeptide.
- aoHGE polypeptides may be administered in certain doses or with particular adjuvants and immunomodulators, for example with interferon-gamma or interleuken-12 (T H 1 response) or interleukin-4 or interleuken-10 (T H 2 response) .
- overlapping fragments of the aoHGE polypeptides of this invention are constructed as described herein.
- the polypeptides that contain B cell epitopes may be identified in a variety of ways for example by their ability to (1) remove protective antibodies from polyclonal antiserum directed against the polypeptide or (2) elicit an immune response which is effective to prevent or lessen the severity of aoHGE infection.
- polypeptides may be used to produce monoclonal antibodies which are screened for their ability to confer protection against aoHGE infection when used to immunize naive animals. Once a given monoclonal antibody is found to confer protection, the particular epitope that is recognized by that antibody may then be identified.
- the polypeptides that contain T cell epitopes may be identified in vi tro by testing them for their ability to stimulate proliferation and/or cytokine production by T cell clones generated from humans of various HLA types, from the lymph nodes, spleens, or peripheral blood lymphocytes of C3H or other laboratory mice, or from domestic animals.
- Compositions comprising multiple T cell epitopes recognized by individuals with different Class II antigens are useful for prevention and treatment of human granulocytic ehrlichiosis in a broad spectrum of patients .
- an aoHGE polypeptide containing a B cell epitope is fused to one or more other immunogenic aoHGE polypeptides containing strong T cell epitopes.
- the fusion protein that carries both strong T cell and B cell epitopes is able to participate in elicitation of a high titer antibody response effective to neutralize infection with aoHGE.
- Strong T cell epitopes may also be provided by non-aoHGE molecules. For example, strong T cell epitopes have been observed in hepatitis B virus core antigen (HBcAg) .
- B cell epitopes of the aoHGE polypeptides are fused to segments of HBcAG or to other antigens which contain strong T cell epitopes, to produce a fusion protein that can elicit a high titer antibody response against aoHGE.
- aoHGE polypeptides of this invention may be prepared by recombinant means, chemical means, or combinations thereof.
- the polypeptides may be generated by recombinant means using the DNA sequences of aoHGE isolate NCH-1 as set forth in the sequence listings contained herein.
- DNA encoding serotypic variants of the polypeptides may likewise be cloned, e.g., using PCR and oligonucleotide primers derived from the sequences herein disclosed.
- Oligonucleotide primers and other nucleic acid probes derived from the genes encoding the aoHGE polypeptides of this invention may also be used to isolate and clone other related proteins from aoHGE an. ' related rickettsia which may contain regions of DNA sequence homologous to the DNA sequences of this invention.
- the DNA sequences of this invention may also be used in PCR reactions to detect the presence of aoHGE in a suspected infected sample. If the aoHGE polypeptides of this invention are produced recombinantly, they may be expressed in unicellular hosts. As is well known to one of skill in the art, in order to obtain high expression levels of foreign DNA sequences m a host, the sequences are generally operatively linked to transcriptional and translational expression control sequences that are functional in the chosen host. Preferably, the expression control sequences, and the gene of interest, will be contained in an expression vector that further comprises a selection marker.
- the DNA sequences encoding the polypeptides of this invention may or may not encode a signal sequence. If the expression host is eukaryotic, it generally is preferred that a signal sequence be encoded so that the mature protein is secreted from the eukaryotic host. An ammo terminal methionine may or may not be present on the expressed polypeptides of this invention. f Lue terminal methionine is not cleaved by the expression host, it may, if desired, be chemically removed by standard techniques. A wide variety of expression host/vector combinations may be employed in expressing the DNA sequences of this invention.
- Useful expression vectors for eukaryotic hosts include, for example, vectors comprising expression control sequences from SV40, bovme papilloma virus, adenovirus, adeno-associated virus, cytomegalovirus and retroviruses including lentiviruses .
- Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from E.
- coli including pBluesc ⁇ pt, pGEX-2T, pUC vectors, col El, pCRl, pBR322, pMB9 and their derivatives, pET- 15, wider host range plasmids, such as RP4, phage DNAs, e.g., the numerous derivatives of phage lambda, e.g. ⁇ GTIO and ⁇ GTll, and other phages .
- Useful expression vectors for yeast cells include the 2 ⁇ plasmid and derivatives thereof.
- Useful vectors for insect cells include pVL 941.
- any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence when operatively linked to it — may be used in these vectors to express the DNA sequences of this invention.
- Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors.
- useful expression control sequences include, for example, the early and late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC or TRC system, the T3 and T7 promoters, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate k ase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast ⁇ - matmg system and other constitutive and mducible promoter sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.
- the early and late promoters of SV40 or adenovirus the lac system, the trp system, the TAC or TRC system, the T3 and T7 promoters, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promote
- DNA sequences encoding the aoHGE polypeptides of this invention are cloned in the expression vector lambda ZAP II (Stratagene, La Jolla, CA) , in which expression from the lac promoter may be induced by IPTG.
- DNA encoding the aoHGE polypeptides of this invention is inserted in frame into an expression vector that allows high level expression of the polypeptide as a glutathione S- transferase fusion protein.
- a fusion protein thus contains amino acids encoded by the vector sequences as well as amino acids of the aoHGE polypeptide.
- a wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of E.
- the host in selecting a vector, the host must be considered because the vector must be replicated in it.
- the vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered.
- an expression control sequence a variety of factors should also be considered. These include, for example, the relative strength of the promoter sequence, its controllability, and its compatibility with the DNA sequence of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the DNA sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the DNA sequences of this invention.
- the molecules comprising the aoHGE polypeptides encoded by the DNA sequences of this invention may be isolated from the fermentation or cell culture and purified using any of a variety of conventional methods including: liquid chromatography such as normal or reversed phase, using HPLC, FPLC and the like; affinity chromatography (such as with inorganic ligands or monoclonal antibodies) ; size exclusion chromatography; immobilized metal chelate chromatography; gel electrophoresis ; and the like.
- liquid chromatography such as normal or reversed phase, using HPLC, FPLC and the like
- affinity chromatography such as with inorganic ligands or monoclonal antibodies
- size exclusion chromatography such as with inorganic ligands or monoclonal antibodies
- immobilized metal chelate chromatography immobilized metal chelate chromatography
- gel electrophoresis and the like.
- the aoHGE polypeptides may be generated by any of several chemical techniques. For example, they may be prepared using the solid-phase synthetic technique originally described by R. B. Mer ⁇ field, "Solid Phase Peptide Synthesis. I. The Synthesis Of A Tetrapeptide", J. Am. Chem. Soc. 83, pp. 2149-54 (1963) , or they may be prepared by synthesis in solution. A summary of peptide synthesis techniques may be found in E. Gross & H. J. Memhofer, 4 The Peptides : Analysis, Synthesis, Biol ogy; Modern Techniques Of Peptide And Ammo Acid Analysi s, John Wiley & Sons, (1981) and M. Bodanszky, Principles Of Peptide Synthesis, Sp ⁇ nger-Verlag (1984).
- these synthetic methods comprise the sequential addition of one or more ammo acid residues to a growing peptide chain.
- peptide coupling agents are used to facilitate this reaction.
- peptide coupling agents suitable for the uses described herein see M. Bodansky, supra .
- a suitable, selectively removable protecting group is utilized for ammo acids containing a reactive side g ⁇ oup, e.g., lysine.
- antibodies directed against the aoHGE polypeptides are generated. Such antibodies are immunoglobulin molecules or portions thereof that are immunologically reactive with an aoHGE polypeptide of the present invention. It should be understood that the antibodies of this invention include antibodies immunologically reactive with fusion proteins and multimeric proteins comprising an aoHGE polypeptide. Antibodies directed against an aoHGE polypeptide may be generated by a variety of means including infection of a mammalian host with aoHGE, or by immunization of a mammalian host with an aoHGE polypeptide of the present invention.
- Such antibodies may be polyclonal or monoclonal, it is preferred that they are monoclonal.
- compositions and re granulocytic e r..: example, the level of aoHGE in infected ticks may be decreased by allowing them to feed on the blood of animals immunized with the aoHGE polypeptides of th.._ invention.
- the antibodies of this invention also hav- variety of other uses. For example, they are use- reagents to screen for expression of the aoHGE polypeptides, either in libraries constructed from aoHGE DNA or from other samples in which the protei- may be present.
- the antibodies of this mventio- are also useful to purify or remove polypeptides frc- given sample, to block or bind to specific epitopes z - the polypeptides and to direct various molecules, sue as toxins, to the surface of aoHGE .
- mice are preferred as ar animal model.
- any animal that is susceptible to infection with aoHGE nay be useful mice are not only susceptible to aoHGE infection but are also afflicted with clinical symptoms of a d ⁇ sea_ that is remarkably similar to human granulocytic ehrlichiosis in humans.
- the humoral r esDO" of mice infected with aoHGE by tick transmission has been shown to be strongly similar to the human hjrc response.
- a polypeptide is use:, . _::ere with a pharmaceutically c z z z _, 3 z.c as complete or incomplete Fre building::' I muramyl dipeptides) or I ⁇ 3I ⁇ .g complexes ) .
- Such adjuvants ma ;p: ⁇ e from rapid dispersal by sea::a-.
- tr.a the immunization sche:_- ⁇ .. :r more administrations cf ⁇ " :cread out over several weeks.
- _ e - - ⁇ D or antibodies of this invention have : - to e effective in the screening prc: ⁇ . : ⁇ e used in a therapeutically erf-: pharmaceutical compositions and ⁇ - _ prevent human granulocytic ehrl_ ⁇ invention may be _ "er.tional depot forms.
- Such dosage forms may include ,:e_ ⁇ t ⁇ cally acceptable carriers and adjuvants : . . are known to those of skill in the art.
- eietable fatty acids water, salts or e_ trcyt s such as protamine sulfate, disodium hyiroge ⁇ phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyr roiidone, cellulose-based substances, and polyethylene glycol.
- Adjuvants for topical or gel base fcrr.s may be selected from the group consisting of so ⁇ -:n ⁇ carboxymethylcellulose, polyacrylates, pc-_. oxyethylene-polyoxypropylene-block polymers, pc_.ethyiene glycol, and wood wax alcohols.
- the vaccines and compositions of this invention may also include other components or be s c:e:t to other treatments during preparation to er.r.ar.oe their immunogenic character or to improve their tc_ .ra ee in patients.
- compositions comprising an antibody of this in .::::: may be administered by a. variety of dosage ::. - and regimens similar to those used for other p . . :z irrmunotherapies and well known to those of
- the aoHGE polypeptides may be formulated and administered to the patient using methods and compositions similar to those employed for other pharmaceutically important polypeptides (e.g., the vaccine against hepatitis) .
- Any pharmaceutically acceptable dosage route including parenteral, intravenous, intramuscular, mtralesional or subcutaneous injection, may be used to administer the polypeptide or antibody composition.
- the composition may be administered to the patient in any pharmaceutically acceptable dosage form including those which may be administered to a patient intravenously as bolus or by continued infusion over a period of hours, days, weeks or months, intramuscularly -- including paravertebrally and periarticularly — subcutaneously, intracutaneously, mtra-articularly, trasynovially, mtrathecally, mtralesionally, periostally or by oral or topical routes.
- the compositions of the invention are in the form of a unit dose and will usually be administered to the patient intramuscularly.
- aoHGE polypeptides or antibodies of this invention may be administered to the patient at one time or over a series of treatments.
- the most effective mode of administration and dosage regimen will depend upon the level of lmmunogenicity, the particular composition and/or adjuvant used for treatment, the severity and course of the expected infection, previous therapy, the patient's health status and response to immunization, and the judgment of the treating physician.
- the more highly immunogenic the polypeptide, the lower ⁇ or of immunizations, ecessary treatment time will ⁇ e -5 administered with an osa ⁇ 'lli consist of 10 ⁇ g - . -y eptide, and preferably, -1000 ⁇ g.
- an osa ⁇ 'lli consist of 10 ⁇ g - . -y eptide, and preferably, -1000 ⁇ g.
- Useful I5C0M, simple metal salts ⁇ oil based adjuvants - " round's adjuvant.
- -s ea the polypeptide -Ision with the
- E. coli excressmg proteins corner- :_ng an aoriGE polypeptide are administered orally to nc-"-man -nimals according to "etno ⁇ s -nnown _n tne art, decrease or lessen the :e'er-ty of ao- ' C ⁇ infect- Fir example, a palatable re:. er.
- oa::er ⁇ a expre _ng an aoHGE polypeptide, a-ine or -n ::e form of a --5 ion protein or multimeric protein, may oe aomm_ste: - .Mtn animal food to be oon:-me ⁇ cy ⁇ __ ⁇ mice or "er animals that harbor
- .ot e -mbodiment
- the antibodies of :;.:.- on as well as the aoHGE polypeptides of :n. .tio.n, and the DNA sequences encoding them are . .5 diagnostic agents for detecting infect::: oHG ⁇ .
- the polypeptides are capable of bindm: co ⁇ y molecules produced in animals, including tnat are infected with aoHGE, and the an:: are oapabie of binding to aoHGE or an_.ige..s :
- agents may be included in a kit which may also e instructions for use and other appropriate ; , preferably a means for detecting when tne tioe or antibody is bound.
- the • :e :r antibody may be labeled with a detection m- .: allows for the detection of the polypeptide :•.
- the detection means may be a fluorescent labeling agent such as fluorescem isocyanate (FIC) , fluorescein isothiocyanate (FITC) , and the like, an enzyme, such as horseradish peroxidase (HRP) , glucose oxidase or the like, a radioactive element such as 125I or Cr that produces gamma ray emissions, or a radioactive element that emits positrons which produce gamma rays upon encounters with electrons present in the test solution, such as C, 0, or N. Binding may also be detected by other methods, for example via avid -biotm complexes.
- FIC fluorescem isocyanate
- FITC fluorescein isothiocyanate
- an enzyme such as horseradish peroxidase (HRP) , glucose oxidase or the like, a radioactive element such as 125I or Cr that produces gamma ray emissions, or a radioactive element that emits posi
- monoclonal antibody molecules produced by a hybridoma can be metabolically labeled by incorporation of radioisotope-conta mg ammo acids m the culture medium, or polypeptides may be conjugated or coupled to a detection means through activated functional groups.
- the diagnostic kits of the present invention may be used to detect the presence of a quantity of aoHGE or anti-aoHGE antibodies a oody fluid sample such as serum, plasma or urine.
- a oody fluid sample such as serum, plasma or urine.
- an aoHGE polypeptide or an antibody of the present invention is bound to a solid support typically by adsorption from an aqueous medium.
- Useful solid matrices are well known in the art, and include crosslmked dextran; agarose; polystyrene; polyvmylchlo ⁇ de; cross-linked polyacrylamide; nitrocellulose or nylon-based materials; tubes, plates or the wells of microtiter plates.
- polypeptides or antibodies of the present invention may be used as diagnostic agents in solution form or as a substantially dry powder, e.g., in lyophilized form.
- aoHGE polypeptides and antibodies directed against those polypeptides provide much more specific diagnostic reagents than whole aoHGE and thus may alleviate such pitfalls as false positive and false negative results.
- aoHGE polypeptides of this invention that are selectively expressed in the infected host and not in cultured aoHGE, and antibodies directed against such polypeptides, allow detection of antigens and antibodies m samples that are undetectable by diagnostic methods using lysates of cultured spirochetes as the antigen.
- One skilled m the art will realize that it may also be advantageous in the preparation of detection reagents to utilize epitopes from more than one aoHGE protein and antibodies directed against such epitopes. It may be particularly advantageous to use epitopes of aoHGE polypeptides that elicit antibodies early in aoHGE infection m combination with epitopes from other aoHGE polypeptides that elicit antibodies that occur m the later stages of human granulocytic ehrlichiosis. Diagnostic reagents containing multiple epitopes which are reactive with antibodies appearing at different are useful to detect the presence of anti-aoHGE antibodies throughout the course of infection and to diagnose human granulocytic ehrlichiosis at all stages.
- a diagnostic kit comprising diagnostic reagents to detect aoHGE as well as other pathogens found in the same tick vector, for example, Borrelia burgdorferi and Babesia mi croti , and instructions for their use.
- the polypeptides and antibodies of the present invention, and compositions and methods comprising them, may also be useful for detection, prevention, and treatment of other infections caused by ⁇ ckettsia which may contain surface proteins sharing ammo acid sequence or conformational similarities with the aoHGE polypeptides of the present invention, for example, Ehrlichia equi and Ehrli chia phagocytophila .
- the following examples are set forth. These examples are for purposes of illustration only, and are not to be construed as limiting the scope of the invention in any manner.
- mice We established the laboratory mouse as an animal model in which to investigate the pathogenesis of HGE and to screen the aoHGE polypeptides and antibodies of the present invention for their ability to elicit an immune response effective to treat or protect against aoHGE infection and/or human granulocytic ehrlichiosis. We chose to use mice because of the extensive lmmunologic, biologic and genetic parameters available for manipulation.
- mice We examined the susceptibility of various strains of mice to infection with the NCH-1 isolate of the HGE agent. We inoculated the mice via tick-borne infection or syringe oculatin by several different routes. [S.W. Barthold et al . , J. Inf .Pis. , (in press).] We chose mice having maximum genetic disparity and representing different H-2 haplotypes. The mice used for these studies included C3H/HeJ, C3H/HeN and C3H/Smn.CIcrHsd/sc ⁇ d mice, purchased from the Jackson Laboratory (Bar Harbor, ME.), NCI Animal Production Program, Frederick Cancer Research Center (Fede ⁇ ck, MD) , and Harlan Sprague Dawley, Inc. (Indianapolis,
- CD-I mice were purchased from Charles River Breeding Laboratories (Wilmington, MA) .
- mice To examine the course of tick-borne aoHGE infection, we placed 5 aoHGE-mfected nymphal ticks on naive C3H mice and allowed them to feed to repletion. All of the mice became infected, having visible morulae in peripheral blood smears at 5-10 days after tick feeding. We necropsied 4 mice with verified infection and 4 age-matched control mice at days 5, 10, 17 and 24 after tick feeding.
- mice exhibited transient splenomegaly and we were able to culture aoHGE from peripheral blood and spleen from all mice on days 17 and 24. All infected mice also developed detectable antibodies to aoHGE by day 10.
- Infected mice developed transient hematologic aberrations similar to those described in human HGE including leukopenia, with a reduction in total leukocytes, granulocytes and lymphocytes, and anemia. Morulae were found only granulocytes. At all time points, there was marked hematopoiesis in spleens and bone marrow of all infected mice and the lungs of most infected mice showed perivascular lymphoid nodules indicative of antigenic stimulation.
- mice To assess the susceptibility of mice to syringe inoculation, we inoculated 3-5 week old mice both intraperitoneally and subcutaneously with 0.1 ml of serial dilutions (undiluted, 1:10, 1:100 and 1:000) of blood from aoHGE-mfected SCID mice (10% granulocytes with morulae) .
- aoHGE-mfected SCID mice 10% granulocytes with morulae
- mice We collected blood from the mice on days 7, 14, 17 and 21 after inoculation and examined peripheral blood smears for morulae to establish aoHGE infection. Mice inoculated by both routes became infected, although they appeared to be more susceptible to infection by l.p. inoculation.
- Xenodiagnosis occurrence of aoHGE infection in unmfected ticks which feed on infected mice
- mice remained persistently infected for up to 55 days.
- mice infected with aoHGE by syringe inoculation at days 5, 10, 30 and 60 after inoculation.
- mice remained persistently infected for at least 55 days after inoculation, and had a 100% correlation between infection, seroconversion, and disease.
- mice of various ages We inoculated groups of 4-5 mice at 1 day, 3 days , 5 days, 1 week and 3 weeks of age by l.p. injection with 0.1 ml of infected SCID mouse blood and assessed infection by hematocrit, spleen weight, morulae and PCR at 10 days after inoculation. e ⁇ .:covered that mice moculated at 1 day and 3 days had a significantly higher percent of granulocytes with morulae than older mice. All infected mice had increased spleen weights.
- aoHGE polypeptides that elicit a humoral response in an infected animal, including humans, we probed lysates of aoHGE-infected HL-60 cells with sera from patients infected with aoHGE and from mice experimentally infected with aoHGE .
- HL-60 cells American Type Culture Collection 240-CCL
- Iscove's modified Dulbecco's medium supplemented with 20% fetal bovme serum, with no added antibiotic, maintained at 37°C with 5% carbon dioxide.
- C3H specific pathogen free mice Jackson Laboratories, Bar Harbor, ME
- mice by placing five hardened nymphs on each mouse and allowing the ticks to feed to repletion.
- antibodies m the human anti-aoHGE antisera reacted with aoHGE proteins having molecular weights of 40, 44, 65, 80, 94, 105, 110, 115 and 125 kDa.
- the murine sera additionally reacted with aoHGE proteins with molecular weights of 25, 34 and 35 kDa and proteins with molecular weights between 40 and 44 kDa.
- Sera from mice infected by tick bite, but not sera from mice infected by syringe reacted with an 80 kDa aoHGE protein.
- aoHGE from infected HL-60 cells prepared as described in Example III, as follows.
- aoHGE NCH-1 isolate
- the critical steps were adequate lysis of the HL-60 cells while leaving the aoHGE cells intact so that subsequent incubation with excess RNase and DNase (to eliminate HL-60 RNA and DNA) does not affect the aoHGE.
- the N- terminal amino acid sequence of the 80-kDa protein which we designated the 80-1 polypeptide, is set forth in SEQ ID NO: 7.
- GenBank Genetics Computer Group Program (University of Wisconsin Biotechnology Center, Madison, WI).
- ECPNAK E. coli
- HSP70 human heat shock protein 70.
- the most closely homologous protein identified in the database is the B . burgdorferi HSP- 70.
- a search of the Genbank Database revealed that the 44-1 polypeptide is approximately 70% homologous with a region from ammo acid 130-138 of the major surface protein 2 (MSP-2) of Anaplasma margmal e .
- the 44-2 polypeptide is homologous with a region of MSP-2 from ammo acid 362-372.
- the MSP-2 protein is encoded by a gene which is one member of a large family of genes with a high degree of homology m A. margmal e genome.
- A. margmale is an important veterinary erythroparasitic pathogen and MSP-2 may confer protection against A. margmale infection [G.H.
- aoHGE polypeptides from the NCH-1 isolate and from other strains of aoHGE, which are useful for the detection, treatment or prevention of human granulocytic ehrlichiosis or for the study of the pathenogenesis of the disease may be isolated and sequenced without undue experimentation according to the methods described herein.
- genomic aoHGE DNA may be isolated according to any of a variety of methods known in the art. See, for example, J. Sambrook et al . , supra .
- PCR amplification of the regions of the DNA encoding the 44 kDa aoHGE polypeptide may be performed by any of a variety of methods known m the art.
- ⁇ he D fR product may be isolated and purified according to any methods known in the art, for example, isolating the product by agaraose gel electrophoresis and purifying using gene clean (BIO 101) according to the manufacturer's instructions.
- aoHGE polypeptides To identify immunodominant aoHGE polypeptides, we performed an immunoblot of lysates of aoHGE NCH-1 infected HL-60 cells proteins, prepared as described in Example III, using twenty sera from 13 patients with documented E. chaff eensis infection. Dr. J.G. Olson (CDC, Atlanta, GA) kindly provided the patient sera. None of the E. chaff eensi s sera reacted with the 40, 44, 65 and 80 kDa aoHGE proteins. One sera out of the twenty reacted weakly with the 110 kDa aoHGE protein and another was reactive with a 120-kDa aoHGE protein.
- Immunoscreenmg Kit (Stratagene) . We induced protein production from the recombinant plaques with lOmM IPTG and transferred the proteins to duplicate plaque lifts on nitrocellulose filters according to methods well known in the art.
- Example VIII Cloning of Immunogenic aoHGE Genes Screening of an aoHGE NCH-1 genomic expression library, prepared as described in Example VII, revealed seven clones that reacted with human and mouse antisera.
- one of skill in the art could readily generate a nested set of deletions in the DNA insert with the Erase-A-Base System (Promega, Madison, WI) (e.g., using Smal to generate the 5' blunt end and BstXI to generate a 3' overhang), and then sequence the subclones using, e.g., the Sequenase Kit (United States Biochemical Corp., Cleveland, OH) and reconstruct the entire sequence using MacVector (International Biotechnology, Inc., New Haven, CT) .
- Erase-A-Base System Promega, Madison, WI
- Smal to generate the 5' blunt end and BstXI to generate a 3' overhang
- sequence the subclones using, e.g., the Sequenase Kit (United States Biochemical Corp., Cleveland, OH) and reconstruct the entire sequence using MacVector (International Biotechnology, Inc., New Haven, CT) .
- the sequence of the plasmid inserts from clones E6 and E7 were determined by the Yale Protein Purification and Analysis Facility using the Circumvent Thermal Cycle Dideoxy DNA sequencing kit (New England Biolabs) . Conditions for denaturation, annealing and extension were: 94° C for 30 sec, 55° C for 20 sec, and 72° C for 20 sec, respectively.
- the DNA sequence of clone E6 is set forth in SEQ ID NO: 1.
- the deduced ammo acid sequence is set forth in SEQ ID NO: 2.
- sequences E5-3A, E5-3B, E5- 5A, E5-5B and E5-6 are set forth in Figures 13-17, respectively.
- sequences E5-3B, E5- 5B and E5-6 have regions of substantial homology with regions of the 44-kDa protein.
- nucleotides 400-600 and 900-1300, approximately, of the 44-kDa protein define regions of homology among the sequences.
- Example IX - Expression of the E6 Polypeptide To express the aoHGE genes of this invention, we utilized the pGEX-2T vector, which is capable of directing expression of cloned inserts as glutathione S-transferase fusion proteins [see J. Sears et al., "Molecular Mapping of OspA-Mediated Immunity to Lyme Borreliosis", J. Immunol. , 147, pp. 1995-2000 (1991)].
- the vector also contains a thrombm cleavage site immediately following the GT protein, thus, allowing the recovery of recombinant proteins without the GT fusion partner.
- aoHGE polypeptides of this invention may be recombinantly expressed without a fusion partner using techniques well known m the art.
- Example IX After inducing protein expression as described m Example IX, we place the E. coli in phosphate buffered saline (PBS) with 1% Triton and subject them to sonication. We purify the glutathione S-transferase-aoHGE polypeptide fusion protein (GT-E6) from cell lysates as follows.
- PBS phosphate buffered saline
- GT-E6 glutathione S-transferase-aoHGE polypeptide fusion protein
- mice We generate antibodies directed against the aoHGE polypeptides of this invention as follows.
- mice Frrederick Cancer Research Center
- antibodies directed against aoHGE polypeptides of this invention can be obtained by immunizing mice with cells expressing a DNA sequence encoding an aoHGE polypeptide of this invention.
- I_FA indirect immunofluorescence assay
- mice We then challenge the mice with the various isolates of aoHGE to determine if active immunization elicits a protective immune response against a range of aoHGE isolates. We then sacrifice the mice and evaluate for infection and disease as described supra . We identify protective aoHGE polypeptides by their ability to prevent aoHGE infection or disease.
- mice with purified recombinant aoHGE polypeptides prepared as described in Example 10 we immunize mice with purified recombinant aoHGE polypeptides prepared as described in Example 10, and boost periodically.
- As a control we inject mice with purified glutathione S- transferase. After the final boost, we bleed the mice and prepare an immunoblot as described in Example III, to determine if the mice are synthesizing antibody against the recombinant protein.
- protective recombinant aoHGE polypeptides by their ability to prevent aoHGE infection and disease.
- One way to identify regions of aoHGE proteins that contain protective B-cell epitopes is to determine which regions of the protein are recognized by monoclonal antibodies that confer protection against aoHGE infection.
- Binding of the protective monoclonal antibody to a fragment indicates that the fragment contains a protective (B cell) epitope.
- This example does not necessarily imply that the epitope recognized by the monoclonal antibody is the only protective epitope in the aoHGE protein. Nor does it imply that the region encoding the B-cell epitope recognized by the monoclonal antibody does not also contain a T-cell epitope. However, it does illustrate one method that may be used to identify protective epitopes of aoHGE proteins .
- Another way to identify regions of aoHGE proteins that contain B cell epitopes is to use aoHGE polypeptide fusion proteins to absorb antibodies from protective polyclonal serum.
- the various T7-aoHGE or aoHGE-glutathione S-transferase fusion proteins are coupled to CnBr activated Sepharore in order to construct a column, using standard techniques.
- aoHGE polypeptides of this invention were able to elicit an immune response that is effective to protect against aoHGE infection.
- CFA complete Freund's adjuvant
- IFA incomplete Freund's adjuvant
- mice Fourteen days after the final boost, we bled the mice and examined the sera from each animal for aoHGE antibodies by probing lysates of aoHGE-infected HL-60 cells in immunoblot as descrioed Example I.
- aoHGE-immunized mice had high titers of aoHGE-specifIC antibodies, detectable by immunoblot at a serum dilution of at least 1:2,000.
- mice actively immunized and sham immunized mice by syringe and tick-borne inoculation.
- mice actively immunized with purified, -killed aoHGE with 100 ⁇ l of blood from a mouse that had been infected with aoHGE for 2 weeks.
- mice 10 days after challenge and evaluated for aoHGE infection by PCR using aoHGE specific 16S ribosomal DNA primers [P. Pancholi et al . , "Ixodes dammmi as a Potential Vector of Human Granulocytic Ehrlichiosis, " J. Inf. Dis . , 172, pp.
- mice developed aoHGE infection, based on aoHGE-specific DNA the blood. In contrast, no aoHGE DNA could be detected in the blood of 4 of 5 mice vaccinated with purified, -killed aoHGE .
- tick inoculation we placed 3-4 aoHGE-mfected I. dammmi nymphs which had fed to repletion on CD-I mice that had been infected for 2 weeks with aoHGE .
- the aoHGE infection rate of the ticks was 85% as determined by visual inspection of the salivary glands using the Feulgen reaction [S.R. Telford et al., Proc . Na tl . Acad. Sci . USA, 93, pp. 6209-6214, supra ] .
- the ticks were allowed to engorge to repletion on immunized and control mice.
- mice were examined for aoHGE by PCR using aoHGE specific 16S rDNA, supra .
- aoHGE has a chromosome that migrates at approximately 700 kb in pulse-field gel electrophoresis .
- To determine which epitopes of aoHGE polypeptides are able to elicit such antibodies we immunize mice with the various aoHGE polypeptide fusion proteins, and challenge the mice with various isolates of aoHGE as described, supra .
- mice with aoHGE polypeptide fusion protein were immunized with aoHGE and boost.
- ticks infected with aoHGE as described m Example III, on mice immunized with GT (control), with aoHGE-GT fusion proteins. After feeding to repletion, the ticks are allowed to naturally detach over water. Approximately ten days post-repletion, we homogenize individual ticks in PBS and spot aliquots on slides. We allow the slides to air-dry, fix in cold acetone and assay by direct or indirect immunofluorescence .
- mice were passively immunized with normal mouse serum.
- aoHGE antiserum diluted 1:5 PBS was administered to mice.
- mice were passively immunized with normal mouse serum.
- One day following passive immunization we challenged immunized and control mice with aoHGE by intraperitoneal inoculation with 50 ⁇ l of blood from mice that had been infected with NCH-1 isolate two weeks earlier, an by tick transmission using 3-4 aoHGE infected ticks. Mice were boosted with 200 ⁇ l of aoHGE antiserum diluted 1:5 with PBS on days 4, 8 and 12 after challenge.
- serial dilution PCR amplified DNA was discernible serum from control mice at a dilution of 10 3 -10 8 whereas product could only be obtained from serum of immunized mice up to a dilution of 10 3 .
- the PCR assay can detect a single aoHGE organism. Accordingly, passive immunization either conferred complete protection or lessened the severity of aoHGE infection.
- mice In terms of clinical symptoms, the control mice but not the protected mice exhibited neutropenia (462 cell/mm 3 ⁇ 280 SD compared 3,240 cells/mm 3 ⁇ 1,340 SD) and splenomegaly (0.27 g ⁇ 0.05 SD compared to 0.12g ⁇ 0.03 SD) .
- anti-aoHGE monoclonal antibodies by fusion of spleen cells from mice infected with aoHGE to mouse P3X63Ag8 myeloma cells, according to methods well known to those of skill in the art. We then determine the isotypes of the monoclonals, and select antibodies reactive with aoHGE for aoHGE immunization studies .
- mice We then passively immunize mice with supernatant from monoclonal antibody producing cells, and challenge the animals with aoHGE. We then sacrifice the mice and examine the blood and tissues for signs of aoHGE infection and disease.
- mice immunized with recombinant aoHGE polypeptides confers protection.
- One of skill in the art would understand that to detect a protective effect, one can vary the experimental conditions.
- antiserum by immunization with a recombinant polypeptide without GT, collect antiserum at a different time point when the titer is higher, passively immunize with more antiserum, decrease the aoHGE challenge dose, or other means known in the art.
- the gene fragments could be cloned into pGEMEX (Promega, Madison, WS) and expressed as T7 gene 10 fusion proteins. Such proteins would be insoluble and thus easily purified by recovery of the insoluble pellet fraction followed by solubilization m denaturants such as urea.
- the fragments could be expressed as glutathione S-transferase fusion proteins as described above. We then transform appropriate host cells and induce expression of the fragments.
- One way to identify fragments that contain protective B-cell epitopes is to use the individual purified fragments to actively immunize mice, as described above. After challenge of the mice with aoHGE, we determine the presence of infection by blood and spleen cultures in HL-60 cells and by examination of peripheral blood smears for granulocytic morulae.
- Another technique to identify protective epitopes is to use the various fragments to immunize mice, allow ticks infected with aoHGE to feed on the mice, and then determine whether the immune response elicited by the fragments is sufficient to cause a decrease in the level of aoHGE in the ticks. Any epitopes which elicit such a response, even if they are not sufficient by themselves to confer protection against subsequent infection with aoHGE, may be useful in a multicomponent vaccine.
- the protective epitopes are able to elicit antibodies that will protect against subsequent infection with isolates of aoHGE other than the isolate from which the protective polypeptide was cloned. We then design a vaccine around those epitopes. If none of the protective epitopes is able to confer protection against infection with other isolates of aoHGE, it may be particularly advantageous to isolate the corresponding aoHGE polypeptides from those isolates. A multicomponent vaccine may then be constructed that comprises multiple epitopes from several different aoHGE isolates. Such a vaccine will, thus, elicit antibodies that will confer protection against a variety of different isolates.
- Example XXIV Identification of T cell epitopes Stimulation in animals of a humoral immune response containing high titer neutralizing antibodies will be facilitated by antigens containing both T cell and B cell epitopes.
- T cell lines Shortly after priming, we harvest the lymph nodes and generate m vi tro T cell lines. These T cell lines are then cloned using limiting dilution and soft agar techniques. We use these T cell clones to determine which polypeptides contain T cell epitopes. The T cell clones are stimulated with the various polypeptides and syngeneic antigen presenting cells. Exposure of the T cell clones to the polypeptides that contain T cell epitopes in the presence of antigen presenting cells causes the T cells to proliferate, which we measure by 3 H-Thymidme incorporation. We also measure lymphokine production by the stimulated T cell clones by standard methods .
- T cell epitopes of the polypeptides recognized by human T cells we isolate T cell clones from aoHGE-infected patients of multiple
- T cell epitopes are identified by stimulating the clones with the various polypeptides
- T cell epitopes are then correlated with Class II HLA antigens such as DR, DP, and DQ.
- Class II HLA antigens such as DR, DP, and DQ.
- the correlation is performed by utilization of B lymphoblastoid cell lines expressing various HLA genes.
- a given T cell clone is mixed with the appropriate B lymphoblastoid cell line and an aoHGE polypeptide, the B cell will be able to present the polypeptide to the T cell.
- T cell epitopes may be identified by adoptive transfer of T cells from mice immunized with various of the aoHGE polypeptides of this invention to naive mice, according to methods well known to those of skill in the art. [See, for example, M.S. DeSouza et al., "Long-Term Study of Cell-Mediated Responses to Borrelia burgdorferi in the Laboratory Mouse", Infect. Immun., 61, pp. 1814-22 (1993)].
- T and B cell epitopes After identifying T cell epitopes of the aoHGE polypeptides, we construct recombinant proteins comprising these epitopes as well as the B cell epitopes recognized by neutralizing antibodies. These fusion proteins, by virtue of containing both T cell and B cell epitopes, permit antigen presentation to T cells by B cells expressing surface immunoglobulin. These T cells in turn stimulate B cells that express surface lmmunoglobin, leading to the production of high titer neutralizing antibodies. We also construct fusion proteins from the aoHGE polypeptides by linking regions of the polypeptides determined to contain B cell epitopes to strong T cell epitopes of other antigens.
- oligonucleotide homologous to am o acids 120 to 140 of the Hepatitis B virus core antigen. This region of the core antigen has been shown to contain a strong T cell epitope [D.R. Millich, et al., supra 1.
- the oligonucleotide is then ligated to the 5' and 3' ends of segments of DNA encoding the B cell epitopes recognized by neutralizing antibodies.
- the recombinant DNA molecules are then used to express a fusion protein comprising a B cell epitope from the aoHGE polypeptide and a T cell epitope from the core antigen, thus enhancing the lmmunogenicity of the polypeptide.
- fusion proteins comprising epitopes of the aoHGE polypeptides as well as epitopes of the tetanus toxoid protein.
- Bacterial flagellm are potent stimulators of cellular and humoral responses, and can be used as vectors for protective antigens [S.M.C. Newton, C. Jacob, B. Stocker, "Immune Response To Cholera Toxin Epitope Inserted In Salmonella Flagellm", Science, 244, pp. 70-72 (1989) ] .
- fusion proteins comprising B cell epitopes from one of the aoHGE polypeptides and T cell epitopes from a different aoHGE polypeptide or other immunogenic aoHGE polypeptides.
- fusion proteins comprising T cell epitopes from aoHGE polypeptides and B cell epitopes from an aoHGE polypeptide and/or other immunogenic aoHGE polypeptides. Construction of these fusion proteins is accomplished by recombinant DNA techniques well known to those of skill in the art. Fusion proteins and antibodies directed against them, are used in methods and composition to detect, treat, and prevent human granulocytic ehrlichiosis as caused by infection with aoHGE .
- mice We use 0.1 ml of this suspension to orally inoculate mice. Inoculation may be performed by gavage using a ball tipped metal needle. We boost the mice with the same amount of bacteria on days 10, 20, 30 and 40. We inoculate control mice in a similar fashion with bacteria lacking the pl97-aoHGE polypeptide plasmid. We bleed the mice 7 days after the second and fourth boosts and conduct immunoblots on extracts of aoHGE, as described in Example I, to detect and quantify antibodies against the aoHGE polypeptide. Fourteen days after the last boost, we challenge the mice by inoculation with aoHGE and evaluate for infection and disease.
- AAT TAT TTA ATT TTT TAT AAA AAT AAC TGC CAA TAT TTA TAT GAA GTA 240 Asn Tyr Leu He Phe Tyr Lys Asn Asn Cys Gin Tyr Leu Tyr Glu Val 65 70 75 80
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE DNA (genomic) (ix) FEATURE:
- GAAGAGGAGC AAAGTCCTGC GCTTGATGTG ATAAGTAGTG AATTGCCTAA GGATGACATT 240
- TCTCCTGTGT TTGGAGAAGA AGAGCGTGCC GAAGAAGATT TTGATGTGTA TCAAGATCCA 960 GTAGAAGTGG ATGATGAGGG AGTTGCTGAT TCTTCTGAGG ATTTAGAGGC TGATTCTGGT 1020
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2718096P | 1996-10-01 | 1996-10-01 | |
US27180P | 1996-10-01 | ||
PCT/US1997/017675 WO1998014584A2 (fr) | 1996-10-01 | 1997-09-30 | Compositions et procedes destines a la prevention et au diagnostic de l'ehrlichiose granulocytaire humaine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0932680A2 true EP0932680A2 (fr) | 1999-08-04 |
Family
ID=21836160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97909914A Withdrawn EP0932680A2 (fr) | 1996-10-01 | 1997-09-30 | Compositions et procedes destines a la prevention et au diagnostic de l'ehrlichiose granulocytaire humaine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0932680A2 (fr) |
JP (1) | JP2001502528A (fr) |
AU (1) | AU4741697A (fr) |
CA (1) | CA2268013A1 (fr) |
WO (1) | WO1998014584A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6231869B1 (en) | 1997-03-21 | 2001-05-15 | Corixa Corporation | Compounds and methods for the diagnosis and treatment of ehrlichia infection |
US6673356B1 (en) | 1997-03-21 | 2004-01-06 | Corixa Corporation | Compounds and methods for the diagnosis and treatment of ehrlichia infection |
US6207169B1 (en) | 1997-03-21 | 2001-03-27 | Corixa Corporation | Compounds and methods for the diagnosis and treatment of Ehrlichia infection |
US6277381B1 (en) * | 1997-03-21 | 2001-08-21 | Corixa Corporation | Compounds and methods for the diagnosis and treatment of Ehrlichia infection |
US6204252B1 (en) * | 1997-04-25 | 2001-03-20 | Aquila Biopharmaceuticals, Inc. | Characterization of granulocytic ehrlichia and methods of use |
AU3483599A (en) * | 1998-04-09 | 1999-11-01 | Ohio State Research Foundation, The | Nucleic acids encoding outer membrane protein of human granulocytic ehrlichiosisagent |
US7807810B2 (en) | 1999-04-08 | 2010-10-05 | The Ohio State University Research Foundation | Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby |
US8784828B2 (en) | 2007-05-04 | 2014-07-22 | The Ohio State University Research Foundation | Ehrlichia ewingii proteins, nucleic acids, and methods of their use |
US20140162256A1 (en) | 2011-03-31 | 2014-06-12 | Yasuko Rikihisa | Compositions and methods for the detection of anaplasma platys |
US9133525B2 (en) | 2012-01-26 | 2015-09-15 | Luc Montagnier | Detection of DNA sequences as risk factors for HIV infection |
-
1997
- 1997-09-30 EP EP97909914A patent/EP0932680A2/fr not_active Withdrawn
- 1997-09-30 AU AU47416/97A patent/AU4741697A/en not_active Abandoned
- 1997-09-30 JP JP10516827A patent/JP2001502528A/ja active Pending
- 1997-09-30 CA CA002268013A patent/CA2268013A1/fr not_active Abandoned
- 1997-09-30 WO PCT/US1997/017675 patent/WO1998014584A2/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2268013A1 (fr) | 1998-04-09 |
AU4741697A (en) | 1998-04-24 |
WO1998014584A2 (fr) | 1998-04-09 |
JP2001502528A (ja) | 2001-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5747294A (en) | Compositions and methods for the prevention and diagnosis of lyme disease | |
US6475492B1 (en) | Peptides and assays for the diagnosis of lyme disease | |
KR102460165B1 (ko) | Ospa의 돌연변이 단편 및 이와 관련된 방법 및 용도 | |
US5656451A (en) | OspE, OspF, and S1 polypeptides in borrelia burgdorferi | |
CZ280743B6 (cs) | Imunogen proti lymské boreliose savců | |
CA2294701C (fr) | Antigenes de surface et proteines utiles dans des compositions utilisees pour le diagnostic et la prevention de la maladie de lyme | |
CA2077434C (fr) | Proteines antigeniques de borrelia burgdorferi | |
WO1998014584A2 (fr) | Compositions et procedes destines a la prevention et au diagnostic de l'ehrlichiose granulocytaire humaine | |
CA2112466A1 (fr) | Methodes et compositions pour le diagnostic de la maladie de lyme | |
KR20130125771A (ko) | 다가 키메라 ospc 백시노겐 및 진단 항원 | |
CA2501939C (fr) | Nouvelles proteines immunogenes de leptospira | |
US5780041A (en) | 39-kilodalton antigen specific to Borrelia burgdorferi | |
ES2203704T3 (es) | Proteinas de membrana de leptospira. | |
AU8154801A (en) | Compositions and methods for the prevention and diagnosis of human granulocytic enrlichiosis | |
US6716591B1 (en) | B. burgdorferi polypeptides | |
WO1997042325A1 (fr) | Polypeptides du type b. burgdorferi exprimes in vivo | |
CA2288433A1 (fr) | Compositions et procedes d'immunisation contre les tiques et de prevention des maladies vehiculees par les tiques | |
AU645078C (en) | Antigenic proteins of (borrelia burgdorferi) | |
AU4392093A (en) | Compositions useful in diagnosis and prophylaxis of lyme disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990428 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SUN, WEI Inventor name: IJDO, JACOB Inventor name: BARTHOLD, STEPHEN, W. Inventor name: FIKRIG, EROL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20030707 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1021647 Country of ref document: HK |